Elheet, A., Bendary, A., Moustafa, S., M.Kabil, H. (2021). Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. Benha Journal of Applied Sciences, 6(5), 55-62. doi: 10.21608/bjas.2021.198231
A.A. Elheet; A.M. Bendary; S.A. Moustafa; H. M.Kabil. "Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention". Benha Journal of Applied Sciences, 6, 5, 2021, 55-62. doi: 10.21608/bjas.2021.198231
Elheet, A., Bendary, A., Moustafa, S., M.Kabil, H. (2021). 'Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention', Benha Journal of Applied Sciences, 6(5), pp. 55-62. doi: 10.21608/bjas.2021.198231
Elheet, A., Bendary, A., Moustafa, S., M.Kabil, H. Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. Benha Journal of Applied Sciences, 2021; 6(5): 55-62. doi: 10.21608/bjas.2021.198231
Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
1Mahala Cardiac Center, Specialized Medical Councils, Ministry of Health and Population, Egypt
2Cardiovascular Medicine Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
3Cardiovascular Medicine Dept., Faculty of Medicine, Damietta Univ., Damietta, Egypt
Abstract
Background: This is a single center, observational prospective study that aimed primarily to study role of Galectin-3 (as a simple marker of inflammation and fibrosis) in prediction of the occurrence of LV remodeling after anterior ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI) for Left anterior descending artery (LAD) or left main (LM) as infarct related artery. Patients and methods: The present study protocol yielded 2 groups of patients: First group, consists of patients found to have LVR with high galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM. Second group consists of patients found to have no LVR with low levels of galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM. Results: Baseline and 6 months EF were significantly higher in the no LVR (57±8 &55 ±8 respectively) group than the LVR group (44 ±7&37 ±8 respectively), P values were <0.001 for each. At 6-month ESV was significantly higher in the LVR group (94 ml) than the no LVR group (42 ml), P-value was <0.001. The median percent change was significantly higher in the LVR group (88.89 %) than the no LVR (5 %). EDV, the mean at 6 months was significantly higher in the LVR group (150 ml) than the no LVR group (94 ml), P-value was <0. 001.The median percent change was significantly higher in the LVR group (77.78%) than the no LVR (0.94%), P-value was <0.00. As regards gelactin-3, the median at baseline was significantly higher in the LVR group (21.8 ng/ml) than the no LVR group (9.6 ng/ml), P-value was <0.001 Table (8). The median percent change was significantly higher in the no LVR group (8.49%) than the LVR group (-31.4%). Conclusion: Gal-3 serum levels after pPCI were independently associated with LVR in patients with anterior STEMI and inversely related to LVEF after a STEMI. Therefore, this study opens the door for a hard question: could we use Gal-3 as part of a screening strategy to identify patients with anterior STEMI who are at higher risk of developing HF after STEMI.
View on SCiNiTO
Top